Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2006-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.105.098541PMID 16439618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of Marijuana Use Disorders in the United States: 1991–1992 and 2001–2002

  2006cited by this paper
• Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor‐independent mechanism

  2005cited by this paper
• Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of Δ9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract

  2005cited by this paper
• Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: In vivo evidence of involvement of P‐glycoprotein in risperidone disposition

  2005cited by this paper
• Olanzapine Penetration into Brain is Greater in Transgenic Abcb1a P-glycoprotein-Deficient Mice than FVB1 (Wild-Type) Animals

  2004cited by this paper
• Glutamate signaling to ras-MAPK in striatal neurons

  2004cited by this paper
• Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines

  2004cited by this paper
• Cannabinoids and immune function.

  2003cited by this paper
• Pharmacokinetics and Pharmacodynamics of Cannabinoids

  2003cited by this paper
• Effect of E6, a novel calmodulin inhibitor, on activity of P-glycoprotein in purified primary cultured rat brain microvessel endothelial cells.

  2003cited by this paper
• In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

  2002influential reference
• Cannabinoid receptors and their ligands.

  2002cited by this paper
• Cannabidiol: An Overview of Some Pharmacological Aspects

  2002cited by this paper
• The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans.

  2002cited by this paper
• Functional expression and localization of P‐glycoprotein at the blood brain barrier

  2002influential reference
• Therapeutic aspects of cannabis and cannabinoids

  2001cited by this paper
• Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.

  2001cited by this paper
• Cannabinoid-induced alterations in brain disposition of drugs of abuse.

  2001cited by this paper
• Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

  2001cited by this paper
• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.

  2001cited by this paper
• Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.

  2000cited by this paper
• Neuroprotective Antioxidants from Marijuana a

  2000cited by this paper
• Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

  2000cited by this paper
• Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs.

  1998cited by this paper
• Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

  1997cited by this paper
• Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.

  1997cited by this paper
• Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system.

  1997cited by this paper
• MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

  1996cited by this paper
• Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells.

  1996cited by this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995cited by this paper
• Multidrug resistance and the role of P-glycoprotein knockout mice.

  1995cited by this paper
• ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells.

  1994cited by this paper
• Structure and function of P-glycoprotein in normal liver and small intestine.

  1993influential reference
• P-glycoprotein expression in human, mouse, hamster and rat hepatocytes in primary culture.

  1993influential reference
• Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier.

  1992cited by this paper
• Controlled clinical trial of cannabidiol in Huntington's disease.

  1991cited by this paper
• Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

  1989influential reference
• Identification of P-glycoprotein in renal brush border membranes.

  1989influential reference
• Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs.

  1988cited by this paper
• Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein.

  1983cited by this paper

• Cannabidiol in Neurology: Current Insights and Translational Perspectives.

  2026cites this paper
• Cannabidiol and Δ9-tetrahydrocannabinol induce drug-metabolizing enzymes, but not transporters, in human hepatocytes: Implications for predicting complex cannabinoid-drug interactions.

  2025cites this paper
• Targeting Epigenetic Plasticity to Reduce Periodontitis-Related Inflammation in Diabetes: CBD, Metformin, and Other Natural Products as Potential Synergistic Candidates for Regulation? A Narrative Review

  2025cites this paper
• An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans

  2025cites this paper
• Cannabidiol (CBD) as a potential therapeutic agent for liver cancer: a comprehensive review of current evidence

  2025cites this paper
• Effect of caffeine and cannabidiol (CBD) co-administration on Δ9-tetrahydrocannabinol (Δ9-THC) subjective effects, performance impairment, and pharmacokinetics

  2025cites this paper
• Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications.

  2025cites this paper
• The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.

  2025cites this paper
• Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention

  2024cites this paper
• Evidence of Potential Drug Interactions Between Cannabidiol and Other Drugs: A Scoping Review to Guide Pharmaceutical Care

  2024cites this paper
• Adverse Ocular Impact and Emerging Therapeutic Potential of Cannabis and Cannabinoids: A Narrative Review

  2024cites this paper
• Drug Interactions in People on Cannabidiol: Is There Cause for Concern?

  2024cites this paper
• Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs

  2024cites this paper
• Phytocannabinoids as Chemotherapy Adjuncts—A Review for Users

  2024cites this paper
• The immunomodulatory effects of cannabidiol on Hsp70-activated NK cells and tumor target cells.

  2024cites this paper
• In vitro Effect of Cannabidiol on Red Blood Cells: Implication in Long-Lasting Pathology Treatment.

  2024cites this paper
• Cannabichromene from full-spectrum hemp extract exerts acute anti-seizure effects through allosteric activation of GABAA receptors

  2024cites this paper
• Molecular Targets for Cannabinoids in Natural Killer Cells: Do They Modulate the Antitumor Activity?

  2024cites this paper
• Cannabidiol: metabolism and clinical efficacy in epileptic patients

  2024cites this paper
• Oral delivery of cannabidiol: Revealing the formulation and absorption challenges

  2024cites this paper
• Human Data on Pharmacokinetic Interactions of Cannabinoids: A Narrative Review.

  2024cites this paper
• Cannabis use in liver transplant candidates and recipients

  2024cites this paper
• Adverse events associated with the use of cannabis-based products in people living with cancer: a scoping review protocol

  2023cites this paper
• Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions

  2023cites this paper
• Cannabidiol–drug interaction in cancer patients: A retrospective study in a real‐life setting

  2023cites this paper
• Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics

  2023cites this paper
• Utilizing an acute hyperthermia-induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome

  2023cites this paper
• Pharmacovigilance of unlicensed cannabidiol in European countries

  2023cites this paper
• Drug interactions with Cannabis sativa: Mechanisms and clinical implication

  2023cites this paper
• Anticoagulant drug–drug interactions with cannabinoids: A systematic review

  2023influential citation
• Role of TRP Channels in Liver-Related Diseases

  2023cites this paper
• Cannabidiol's impact on drug-metabolization.

  2023cites this paper
• Predicting Maternal and Infant Tetrahydrocannabinol Exposure in Lactating Cannabis Users: A Physiologically Based Pharmacokinetic Modeling Approach

  2023cites this paper
• O sistema endocanabinoide e as dores orofaciais: atualidades e perspectivas

  2023cites this paper
• Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC

  2022cites this paper
• Biological Effects of Cannabidiol on Human Cancer Cells: Systematic Review of the Literature.

  2022cites this paper
• Overview of the Endocannabinoid System and Endocannabinoidome

  2022cites this paper
• [Pharmacology of cannabidiol: Red flags, consequences and risks in humans].

  2022cites this paper
• Cannabidiol drug interaction considerations for prescribers and pharmacists

  2022cites this paper
• In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1.

  2022cites this paper
• Evaluating Cannabis sativa L.'s neuroprotection potential: From bench to bedside.

  2022cites this paper
• Herb-anticancer drug interactions in real life based on VigiBase, the WHO global database

  2022cites this paper
• A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors

  2022cites this paper
• Cannabinoid-Based Medicine: Pharmacology and Drug Interactions

  2022cites this paper
• Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways.

  2021cites this paper
• Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2)

  2021cites this paper
• Marijuana Use in Patients with Cardiovascular Disease: Current Knowledge and Gaps

  2021cites this paper
• The characteristics of Raman spectroscopy of isomer CBD- and THC-Au nanoparticles using the density functional theory.

  2021cites this paper
• Late presentation of posterior reversible encephalopathy syndrome following liver transplantation in the setting of tacrolimus and cannabis use

  2021cites this paper
• Cannabis Drug Interactions

  2021cites this paper
• Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  2021cites this paper
• Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process

  2021cites this paper
• Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization

  2021cites this paper
• Buprenorphine-Related Deaths in North Carolina from 2010-2018.

  2021cites this paper
• Cannabidiol-induced toxicity: who is the culprit?

  2021cites this paper
• Vitamin E TPGS and its applications in nutraceuticals

  2021cites this paper
• Cannabidiol modifies the seizure expression and effects of antiseizure drugs in a rat model of recurrent severe seizures.

  2021cites this paper
• Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.

  2021cites this paper
• Medicinal Cannabis: an overview for health-care providers

  2021cites this paper
• Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions

  2020cites this paper
• Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week.

  2020cites this paper
• Cannabidiol in the Treatment of Epilepsy: Current Evidence and Perspectives for Further Research.

  2020cites this paper
• The Pharmacodynamics, Pharmacokinetics, and Potential Drug Interactions of Cannabinoids

  2020cites this paper
• In Vitro Screening of Three Commercial Cannabis-Based Products on ATP-Binding Cassette and Solute-Carrier Transporter Function

  2020cites this paper
• Acute regulation of apical ABC transporters in the gut. Potential influence on drug bioavailability.

  2020cites this paper
• The Anti-Tumor Effects of Cannabidiol when Administered as a Companion Treatment to Standard Chemotherapy: A Case Study in Breast Cancer

  2020cites this paper
• In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants

  2020cites this paper
• Interaction of cannabidiol with other antiseizure medications: A narrative review.

  2020cites this paper
• Dual Inhibitors as a Rational Strategy for Cancer Multidrug Resistance Treatment

  2020cites this paper
• Clinical pharmacology of cannabidiol in refractory epilepsy.

  2020cites this paper
• The effect of cannabidiol on the pharmacokinetics of carbamazepine in rats

  2020cites this paper
• A Δ9-Tetrahydrocannabinol Physiologically-Based Pharmacokinetic Model Development in Humans

  2020cites this paper
• Development of a Physiologically-Based Pharmacokinetic Model of Δ9-Tetrahydrocannabinol in Mice, Rats, and Pigs

  2020cites this paper
• Cannabis against chronic musculoskeletal pain: a scoping review on users and their perceptions

  2020cites this paper
• Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?

  2020cites this paper
• A New Data Repository for Pharmacokinetic Natural Product-Drug Interactions: From Chemical Characterization to Clinical Studies

  2020cites this paper
• The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer

  2020influential citation
• Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database

  2020cites this paper
• Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

  2020cites this paper
• Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions

  2020cites this paper
• High Doses of Δ9-Tetrahydrocannabinol Might Impair Irinotecan Chemotherapy: A Review of Potentially Harmful Interactions

  2020cites this paper
• Title: New Approaches with Natural Product Drugs for Overcoming Multidrug Resistance in Cancer Short running title: Natural Products and Cancer MDR

  2020cites this paper
• Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?

  2020cites this paper
• Uso de maconha em pacientes com doença cardiovascular. Tópico de Revisão Semanal do JACC

  2020cites this paper
• Marijuana use in transplantation: A call for clarity

  2019cites this paper
• Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: pharmacodynamic and pharmacokinetic studies.

  2019cites this paper
• A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents

  2019cites this paper
• Reviewing the mechanisms of natural product-drug interactions involving efflux transporters and metabolic enzymes.

  2019cites this paper
• 2-APB and CBD-Mediated Targeting of Charged Cytotoxic Compounds Into Tumor Cells Suggests the Involvement of TRPV2 Channels

  2019influential citation
• The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.

  2019cites this paper
• Medical Marijuana-Induced Tacrolimus Toxicity.

  2019cites this paper
• Cannabis and Cannabinoids: Kinetics and Interactions.

  2019cites this paper
• The expression of cannabinoid-related genes in multiple disease cell lines

  2019cites this paper
• Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.

  2019cites this paper
• Evidence of a clinically significant drug‐drug interaction between cannabidiol and tacrolimus

  2019cites this paper
• A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

  2019influential citation
• Targeting multidrug resistance in cancer by natural chemosensitizers

  2019cites this paper
• The Psychosocial Evaluation of Transplant Candidates

  2018cites this paper
• Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review

  2018cites this paper
• Inhibition of P-Glycoprotein Mediated Efflux in Caco-2 Cells by Phytic Acid.

  2018cites this paper